



Date: 23rd November, 2022

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001 Script Code : 539872	National Stock Exchange of India Limited 5th Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051 Script Code : BAJAJHCARE
--	---

Dear Sir/Madam,

Sub: Business Updates: Inauguration of new production line for Processing of Opium at Savli, Gujarat, India and commenced the trial run for the same.

In terms of Regulation 30 of SEBI (LODR) Regulations, 2015, please find attached herewith business updates for Inauguration of new production line for Processing of Opium at Savli, Gujarat, India and commenced the trial run for the same.

Kindly take the same on record.

Thanking you.

Yours faithfully,

**For and on behalf of Board of Directors of
Bajaj Healthcare Limited**

**Aakash Keshari
Company Secretary**

Encl: As above

BAJAJ HEALTHCARE LIMITED

Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No: B-39, B-39A, B-39A/1, Road No. 23, Wagle Ind. Estate, Thane (West), Thane - 400604
Tel. : + 91 22 66177400/ 401; Fax : +91 22 66177458; E-mail : bajajhealth@bajajhealth.com

CIN No. L99999MH1993PLC072892



CIN: L99999MH1993PLC072892

Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39A, B-39 A/1, Rd No.23, Wagle Ind. Estate Thane West, Mumbai – 400604.

Business Update

Bajaj Healthcare Limited (“BHL”) announces inauguration and commencement of trial runs- Opium Processing Business for the Government of India (GOI).

Thane, 23rd November, 2022: Bajaj Healthcare Limited (BHL), a leading manufacturer of APIs, Intermediates and Formulations, has announced the inauguration of new production line for Processing of Opium at Savli, Gujarat, India and commenced the trial run for the same.

- BHL had received two letters of Award on 12th July, 2022, for the manufacture of Alkaloids/APIs from Government of India, Department of Revenue, Office of Chief Controller, Govt. Opium & Alkaloid Factories as follows: -
 1. Letter of Award, to manufacture Alkaloids & APIs from processing of 500 MT of unlanded poppy capsule along with Straw on an annual basis.
 2. Letter of Award, to manufacture Alkaloids & APIs from processing of 100 MT of Opium Gum on an annual basis.
- BHL is pleased to inform that it has inaugurated the new production line and commenced the trial operations for Opium Processing/API's under highly regulated conditions & under strict adherence to protocols prescribed by the Government of India.
- The new production line is equipped with the latest advanced manufacturing system to produce quality products of Alkaloids & APIs used in a wide range of pharmaceutical applications.
- The new production line was inaugurated in a ceremony in Savli, Gujarat attended by Mr. Rajnath Singh – Chemical Examiner of Government of India, Opium Processing Plant, Neemuch.



Business Update



Bajaj Healthcare Limited

Commenting on the above business update, Mr. Anil Jain, Joint Managing Director, Bajaj Healthcare said:

"It is with great pride that I announce the successful inauguration and commencement of trial run for the manufacture of Alkaloids/ APIs at our unit in Savli, Gujarat. The commencement of this new production line marks another important milestone for our commitment to growing our business. This facility positions BHL to be a trusted manufacturing/ processing partner for Government of India (GOI), seeking to not only improve their operations, but also to meet their demand for manufacture of Alkaloids/APIs.

This is a very highly regulated segment and we have carried out the trial runs for the same whilst taking due care of all the regulations and protocols, as prescribed by the Government of India. We expect this segment to contribute INR 250Mn to 300Mn by FY25.

We estimate the commercial operations to commence in Q3 FY23 and further anticipate successive orders under similar tenders, to scale up to processing of ~6,000 MT of Poppy Straw & Opium Gum in the next 5 years.

We have been awarded this order on the back of our strong API manufacturing expertise & infrastructural capabilities. With this manufacturing, we plan to establish our footprint in this niche segment of Opiate processing and, with the contribution from our existing, highly skilled workforce; I believe we are well-placed to take the business forward."

About Bajaj Healthcare Limited

Bajaj Healthcare Limited a leading manufacturer of APIs, Intermediates and Formulations established in the year 1993. It specializes in manufacturing of Intermediates, API, formulations & Nutraceuticals. The company has state-of-art manufacturing facilities, of which 6 units are dedicated to APIs, 2 unit to Intermediates and 1 unit for formulation. These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities. BHL has a strong presence globally in countries like Europe, USA, Australia, Africa, Middle East and South America.

For further information on the Company, please visit www.bajajhealth.com

Rupesh Nikam (CFO)

Bajaj Healthcare Limited

Contact: +91 22 6617 7400

Email: investor@bajajhealth.com

Vinayak Shirodkar/ Naman Maheshwari

Captive IR Strategic Advisors Pvt. Ltd.

Contact: +919372467194

Email: vinayak@cap-ir.com / naman@cap-ir.com

Disclaimer:

CERTAIN STATEMENTS IN THIS DOCUMENT MAY BE FORWARD LOOKING STATEMENTS. SUCH FORWARD-LOOKING STATEMENTS ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES LIKE GOVERNMENT ACTIONS, LOCAL POLITICAL OR ECONOMIC DEVELOPMENTS, TECHNOLOGICAL RISKS, AND MANY OTHER FACTORS THAT COULD CAUSE OUR ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTEMPLATED BY THE RELEVANT FORWARD-LOOKING STATEMENTS. BAJAJ HEALTHCARE LTD WILL NOT BE IN ANY WAY RESPONSIBLE FOR ANY ACTION TAKEN BASED ON SUCH STATEMENTS AND UNDERTAKES NO OBLIGATION TO PUBLICLY UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT SUBSEQUENT EVENTS OR CIRCUMSTANCE